CERo Therapeutics’ (CERO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CERo Therapeutics (NASDAQ:CERO) in a research report sent to investors on Friday morning,Benzinga reports. D. Boral Capital currently has a $30.00 price objective on the stock.

A number of other analysts have also weighed in on CERO. Maxim Group initiated coverage on CERo Therapeutics in a research note on Monday, May 19th. They issued a “buy” rating and a $60.00 target price on the stock. D Boral Capital upgraded CERo Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 23rd. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat, CERo Therapeutics has a consensus rating of “Buy” and an average price target of $45.00.

CERo Therapeutics Trading Down 14.6%

CERO stock opened at $5.92 on Friday. The business’s fifty day simple moving average is $8.14 and its two-hundred day simple moving average is $13.21. CERo Therapeutics has a twelve month low of $5.41 and a twelve month high of $895.40.

CERo Therapeutics (NASDAQ:CERO) last released its earnings results on Friday, August 22nd. The company reported ($61.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($70.23) by $8.52.

Institutional Investors Weigh In On CERo Therapeutics

A hedge fund recently bought a new stake in CERo Therapeutics stock. Parallel Advisors LLC acquired a new stake in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 220,000 shares of the company’s stock, valued at approximately $161,000. Parallel Advisors LLC owned approximately 7.26% of CERo Therapeutics at the end of the most recent reporting period. 29.64% of the stock is owned by hedge funds and other institutional investors.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.